Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors acknowledge the contribution of Dr Dominic Spagnolo and Dr Benhur Amanuel who assessed and reported the lymph node histopathology samples at diagnosis and at the second presentation.

Consent

Informed consent was obtained from the patient to publish information and images found in this letter to the editor.

Disclosure statement

No potential conflict of interest was reported by the author(s). Dr Ross T. Salvaris: Honoraria: AbbVie, Roche, AstraZeneca; Dr Benjamin M Allanson: None; Professor Chan Y. Cheah: Honoraria: Roche/Genentech, Janssen-Cilag, TG Therapeutics, Loxo/Lilly, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Menarini, Dizai Pharmaceuticals, Consulting or Advisory Role: Janssen-Cilag, Roche/Genentech, TG Therapeutics, Loxo/Lilly, Gilead Sciences, AstraZeneca, Bristol-Myers Squibb, Ascentage Pharma, Merck, Menarini, Dizai Pharmaceuticals, Research Funding: Roche/Genentech, Bristol-Myers Squibb, Abbvie, Merck, Lilly.

Additional information

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.